Cara Therapeutics Incorporated (NASDAQ:CARA) Shorted Shares Decreased By 2.32%

September 17, 2017 - By Louis Casey

 Cara Therapeutics Incorporated (NASDAQ:CARA) Shorted Shares Decreased By 2.32%

Investors sentiment decreased to 1.26 in 2016 Q4. Its down 0.57, from 1.83 in 2016Q3. It dropped, as 12 investors sold Cara Therapeutics Inc shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 12.12 million shares or 4.42% more from 11.60 million shares in 2016Q3 were reported.
Geode Capital Limited Liability Corp has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Meeder Asset Mngmt Inc owns 1,693 shares. Wall Street Associate, California-based fund reported 124,110 shares. Disciplined Growth Mn invested in 0.19% or 888,125 shares. Blackrock Institutional Trust Comm Na accumulated 754,488 shares. Susquehanna Intll Llp accumulated 105,012 shares or 0% of the stock. The Pennsylvania-based Vanguard Gp has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Alphamark Advisors Limited Liability holds 0.01% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 1,440 shares. Pacad Inv invested 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). Barclays Plc holds 0% in Cara Therapeutics Inc (NASDAQ:CARA) or 66,743 shares. Voya Inv Llc reported 10,670 shares stake. Denmark-based Cam Group Hldg A S has invested 0.06% in Cara Therapeutics Inc (NASDAQ:CARA). Everpoint Asset Management Ltd Llc holds 0.09% or 500,000 shares in its portfolio. Dimensional Fund L P holds 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 229,626 shares. Rho Cap Prtnrs has 21.84% invested in Cara Therapeutics Inc (NASDAQ:CARA) for 3.07M shares.

Since March 31, 2017, it had 1 insider purchase, and 0 insider sales for $9.10 million activity. RHO Ventures VI LP had bought 500,000 shares worth $9.10 million on Friday, March 31.

The stock of Cara Therapeutics Incorporated (NASDAQ:CARA) registered a decrease of 2.32% in short interest. CARA’s total short interest was 9.08M shares in September as published by FINRA. Its down 2.32% from 9.30M shares, reported previously. With 940,700 shares average volume, it will take short sellers 10 days to cover their CARA’s short positions. The short interest to Cara Therapeutics Incorporated’s float is 39.72%.

The stock increased 3.47% or $0.46 on September 15, reaching $13.73. About 1.38 million shares traded or 24.32% up from the average. Cara Therapeutics Inc (NASDAQ:CARA) has risen 206.00% since September 17, 2016 and is uptrending. It has outperformed by 189.30% the S&P500.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $447.34 million. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It currently has negative earnings. It is developing a class of product candidates that target the body’s peripheral nervous system.

Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage

Among 9 analysts covering Cara Therapeutics (NASDAQ:CARA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Cara Therapeutics had 20 analyst reports since July 27, 2015 according to SRatingsIntel. On Friday, August 4 the stock rating was maintained by Canaccord Genuity with “Buy”. Scotia Capital maintained Cara Therapeutics Inc (NASDAQ:CARA) on Thursday, November 24 with “Outperform” rating. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, June 21. Needham maintained it with “Buy” rating and $27 target in Friday, July 24 report. The firm has “Buy” rating by Piper Jaffray given on Friday, August 4. The stock of Cara Therapeutics Inc (NASDAQ:CARA) earned “Buy” rating by Needham on Wednesday, June 21. The rating was maintained by H.C. Wainwright on Friday, June 30 with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, July 13 report. The stock of Cara Therapeutics Inc (NASDAQ:CARA) earned “Buy” rating by Laidlaw on Friday, June 30. The stock has “Buy” rating by H.C. Wainwright on Friday, August 4.

More important recent Cara Therapeutics Inc (NASDAQ:CARA) news were published by: Fool.com which released: “Here’s Why Cara Therapeutics Rose 9.6% in August” on September 07, 2017, also Nasdaq.com published article titled: “Surging Earnings Estimates Signal Good News for Cara Therapeutics (CARA)”, Fool.com published: “Here’s Why the Best Is Yet to Come for Cara Therapeutics, Inc.” on September 10, 2017. More interesting news about Cara Therapeutics Inc (NASDAQ:CARA) was released by: Fool.com and their article: “Big Investors Are Buying Cara Therapeutics Stock. Should You?” with publication date: August 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.